Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002943950 | SCV003278304 | uncertain significance | Brugada syndrome 7 | 2024-05-06 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 31 of the SCN3B protein (p.Ser31Leu). This variant is present in population databases (no rsID available, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with SCN3B-related conditions. ClinVar contains an entry for this variant (Variation ID: 2067333). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004983224 | SCV005500086 | uncertain significance | Cardiovascular phenotype | 2024-12-08 | criteria provided, single submitter | clinical testing | The p.S31L variant (also known as c.92C>T), located in coding exon 2 of the SCN3B gene, results from a C to T substitution at nucleotide position 92. The serine at codon 31 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |